Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Functional annotation of melanoma risk loci identifies novel susceptibility genes.

Fang S, Lu J, Zhou X, Wang Y, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Sui D, Amos CI, Lee JE.

Carcinogenesis. 2019 Oct 21. pii: bgz173. doi: 10.1093/carcin/bgz173. [Epub ahead of print]

PMID:
31630191
2.

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.

Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0340-7. [Epub ahead of print]

PMID:
31383963
3.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
4.

Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression.

Fang S, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, Wargo J, Sui D, Wei Q, Amos CI, Lee JE.

J Invest Dermatol. 2019 Nov;139(11):2352-2358.e3. doi: 10.1016/j.jid.2019.03.1158. Epub 2019 Jun 7.

PMID:
31176707
5.

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018.

PMID:
30959471
6.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
7.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
8.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

9.

A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node.

Bhutiani N, Egger ME, Stromberg AJ, Gershenwald JE, Ross MI, Philips P, Martin RCG 2nd, Scoggins CR, McMasters KM.

J Surg Oncol. 2018 Nov;118(6):922-927. doi: 10.1002/jso.25193. Epub 2018 Sep 27.

PMID:
30259521
10.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

11.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

12.

Metastatic melanoma to the testis.

Patnana M, Korivi BR, Devine CE, Faria S, Prieto V, Ross MI, Ng CS.

BJR Case Rep. 2018 Feb 22;4(3):20170104. doi: 10.1259/bjrcr.20170104. eCollection 2018 Mar.

13.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
14.

Management of Sentinel-Node Metastasis in Melanoma.

Caulley L, Balch CM, Ross MI, Robert C.

N Engl J Med. 2018 Jan 4;378(1):85-88. No abstract available.

PMID:
29298143
15.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

16.

Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes.

Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE.

J Invest Dermatol. 2017 Aug;137(8):1792-1795. doi: 10.1016/j.jid.2017.04.007. Epub 2017 Apr 23. No abstract available.

17.

Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.

Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT.

Clin Cancer Res. 2017 Apr 15;23(8):2093-2104. doi: 10.1158/1078-0432.CCR-16-2126. Epub 2016 Nov 18.

18.

Sentinel lymph node biopsy for ocular adnexal melanoma.

Pfeiffer ML, Ozgur OK, Myers JN, Peng A, Ning J, Zafereo ME, Thakar S, Thuro B, Prieto VG, Ross MI, Esmaeli B.

Acta Ophthalmol. 2017 Jun;95(4):e323-e328. doi: 10.1111/aos.13252. Epub 2016 Oct 24.

19.

Counterpoint: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma.

Ross MI.

Oncology (Williston Park). 2016 Oct 15;30(10):891, 893-5. No abstract available.

20.

Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness.

Fang S, Vaysse A, Brossard M, Wang Y, Deng D, Liu Q, Zhang P, Xu K, Li M, Feng R, Liu H, Dang Y, Chen W, Prieto V, Gershenwald JE, Ross MI, Matejka B, Malke J, Haydu LE, Reveille JD, Sui D, Bassett RL Jr, Koshkina N, Avril MF, Lu M, Wei Q, Demenais F, Amos CI, Lee JE.

J Invest Dermatol. 2017 Jan;137(1):253-257. doi: 10.1016/j.jid.2016.07.032. Epub 2016 Aug 6. No abstract available.

21.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Aug;14(8):945-58.

PMID:
27496110
22.

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Apr;14(4):450-73.

PMID:
27059193
23.

Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.

Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE.

J Clin Oncol. 2016 May 20;34(15):1741-7. doi: 10.1200/JCO.2015.64.1357. Epub 2016 Mar 21.

24.

Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.

McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC 2nd, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Davidson BS, Gershenwald JE, Hagendoorn LJ, Stromberg AJ, Scoggins CR.

J Clin Oncol. 2016 Apr 1;34(10):1079-86. doi: 10.1200/JCO.2015.63.3776. Epub 2016 Feb 8.

25.

Excision Margins of Melanoma Make a Difference: New Data Support an Old Paradigm.

Ross MI, Balch CM.

Ann Surg Oncol. 2016 Apr;23(4):1053-6. doi: 10.1245/s10434-015-4950-0. Epub 2015 Nov 11. No abstract available.

PMID:
26561402
26.

The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients.

Voss RK, Cromwell KD, Chiang YJ, Armer JM, Ross MI, Lee JE, Gershenwald JE, Stewart BR, Shaitelman SF, Cormier JN.

J Surg Oncol. 2015 Dec;112(8):834-40. doi: 10.1002/jso.24068. Epub 2015 Oct 18.

27.

Lymphatic Mapping and Sentinel Node Biopsy in Melanoma.

Balch CM, Ross MI.

JAMA Surg. 2015 Jul;150(7):623-4. doi: 10.1001/jamasurg.2015.0712. No abstract available.

PMID:
26016730
28.

Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study.

Roland CL, Ross MI, Hall CS, Laubacher B, Upshaw J, Anderson AE, Lucci A.

Melanoma Res. 2015 Aug;25(4):335-41. doi: 10.1097/CMR.0000000000000168.

29.

Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes.

Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE.

J Invest Dermatol. 2015 Sep;135(9):2266-2272. doi: 10.1038/jid.2015.138. Epub 2015 Apr 7.

30.

Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema.

Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, Gershenwald JE, Lee JE, Royal RE, Lucci A, Cormier JN.

Eur J Cancer Care (Engl). 2015 Sep;24(5):724-33. doi: 10.1111/ecc.12311. Epub 2015 Mar 24.

31.

C-reactive protein as a marker of melanoma progression.

Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE.

J Clin Oncol. 2015 Apr 20;33(12):1389-96. doi: 10.1200/JCO.2014.58.0209. Epub 2015 Mar 16.

32.

Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis.

Lim L, Nichols B, Migden MR, Rajaram N, Reichenberg JS, Markey MK, Ross MI, Tunnell JW.

J Biomed Opt. 2014;19(11):117003. doi: 10.1117/1.JBO.19.11.117003.

33.

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.

Thompson JF, Agarwala SS, Smithers BM, Ross MI, Scoggins CR, Coventry BJ, Neuhaus SJ, Minor DR, Singer JM, Wachter EA.

Ann Surg Oncol. 2015 Jul;22(7):2135-42. doi: 10.1245/s10434-014-4169-5. Epub 2014 Oct 28.

34.

The relationship between blood IL-12p40 level and melanoma progression.

Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL Jr, Wang LE, Wei Q, Amos CI, Lee JE.

Int J Cancer. 2015 Apr 15;136(8):1874-80. doi: 10.1002/ijc.29182. Epub 2014 Sep 18.

35.

Melanoma, version 4.2014.

Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):621-9.

PMID:
24812131
36.

Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.

Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC Jr, Morton DL, Atkins MB, Flaherty KT, Sondak VK.

Ann Surg Oncol. 2014 Apr;21(4):1075-81. doi: 10.1245/s10434-013-3464-x. Epub 2014 Feb 15.

37.

Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma.

Ross MI.

J Surg Oncol. 2014 Mar;109(4):314-9. doi: 10.1002/jso.23554. Epub 2014 Feb 10. Review.

PMID:
24510477
38.

The palliative index: predicting outcomes of emergent surgery in patients with cancer.

Roses RE, Tzeng CW, Ross MI, Fournier KF, Abbott DE, You YN.

J Palliat Med. 2014 Jan;17(1):37-42. doi: 10.1089/jpm.2013.0235.

39.

Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas.

Chu VH, Tetzlaff MT, Torres-Cabala CA, Prieto VG, Bassett R Jr, Gershenwald JE, McLemore MS, Ivan D, Wang WL, Ross MI, Curry JL.

Biomed Res Int. 2013;2013:898719. doi: 10.1155/2013/898719. Epub 2013 Dec 3.

40.

The role of adjuvant radiotherapy in the local management of desmoplastic melanoma.

Guadagnolo BA, Prieto V, Weber R, Ross MI, Zagars GK.

Cancer. 2014 May 1;120(9):1361-8. doi: 10.1002/cncr.28415. Epub 2013 Oct 18.

41.

Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies.

Rueth NM, Xing Y, Chiang YJ, Cromwell KD, Ross MI, Lee JE, Gershenwald JE, Royal RE, Cormier JN.

Ann Surg. 2014 Jun;259(6):1215-22. doi: 10.1097/SLA.0000000000000233.

PMID:
24096759
42.

An opportunity to ensure high-quality melanoma care through the use of a preoperative treatment algorithm.

Kester BS, Wayne JD, Ross MI, Bentrem DJ, Merkow RP, Bilimoria KY.

Ann Surg Oncol. 2013 Nov;20(12):3976-83. doi: 10.1245/s10434-013-3094-3. Epub 2013 Jul 17.

PMID:
23860805
43.

Age as a prognostic factor in patients with localized melanoma and regional metastases.

Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK.

Ann Surg Oncol. 2013 Nov;20(12):3961-8. doi: 10.1245/s10434-013-3100-9. Epub 2013 Jul 10.

44.

Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma.

Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN.

Melanoma Res. 2013 Aug;23(4):290-7. doi: 10.1097/CMR.0b013e3283632c83.

45.

Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience.

Ross MI, Gershenwald JE.

Clin Dermatol. 2013 May-Jun;31(3):298-310. doi: 10.1016/j.clindermatol.2012.08.004. Review.

PMID:
23608449
46.

Melanoma, version 2.2013: featured updates to the NCCN guidelines.

Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2013 Apr 1;11(4):395-407.

PMID:
23584343
47.

Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.

Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, Valencia KM, McLemore MS, Ross MI, Prieto VG.

Mod Pathol. 2013 Sep;26(9):1153-60. doi: 10.1038/modpathol.2013.59. Epub 2013 Apr 5.

48.

Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.

Ross MI, Wu E, Wilkins JT, Gupta D, Shen S, Aulwes D, Montero K, Holly TA.

J Nucl Cardiol. 2013 Apr;20(2):197-204. doi: 10.1007/s12350-013-9679-1. Epub 2013 Feb 13.

PMID:
23404232
49.

Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.

Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK.

Ann Surg. 2013 Feb;257(2):173-9. doi: 10.1097/SLA.0b013e3182805c4a.

50.

Diversity of stage III melanoma in the era of sentinel lymph node biopsy.

Egger ME, Callender GG, McMasters KM, Ross MI, Martin RC 2nd, Edwards MJ, Urist MM, Noyes RD, Sussman JJ, Reintgen DS, Stromberg AJ, Scoggins CR.

Ann Surg Oncol. 2013 Mar;20(3):956-63. doi: 10.1245/s10434-012-2701-z. Epub 2012 Oct 14.

PMID:
23064795

Supplemental Content

Support Center